Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients

Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect residual BC cells in complete responders. Breast carcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokolenko, Anna P., Moiseyenko, Fedor V., Iyevleva, Aglaya G., Ivantsov, Alexandr O., Dolmatov, Georgiy D., Shelekhova, Ksenia V., Gulo, Elizaveta V., Topal, Anastasya X., Artemieva, Elizaveta V., Abduloeva, Nuriniso H., Rysev, Nikita A., Barsova, Daria A., Levchenko, Natalia V., Volkov, Nikita M., Egorenkov, Vitaliy V., Moiseyenko, Vladimir M., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914941/
https://www.ncbi.nlm.nih.gov/pubmed/36768191
http://dx.doi.org/10.3390/ijms24031870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914941/
https://www.ncbi.nlm.nih.gov/pubmed/36768191
http://dx.doi.org/10.3390/ijms24031870

Ejemplares similares